RxDoctor Payments Data

Andrew Simon, MD

Urology · Brick, NJNPI 1992767388

Payments from drug & device makers

$911in general payments, 2019–2025

Across 32 payments — averaging $28.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$212
  • Stryker$151
  • Johnson & Johnson$144
  • Medtronic$141
  • Neotract Inc.$85
  • Myovant Sciences Inc.$81
  • plus $98 from 5 others

What the payments were for

  • Food & beverage$78286%
  • Education$12914%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$911 in reported general payments places this provider in the 25th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$180,794
Medicare patients
613
Services billed
4,264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron75$81,693
Tamsulosin Hcl694$13,263
Finasteride718$12,103
Methenamine Hippurate25$3,561
Oxybutynin Chloride ErOxybutynin Chloride106$2,899
Testosterone36$2,422
Silodosin14$2,044
Dutasteride61$1,857
Cefaclor25$1,755
Tadalafil14$1,709
Alfuzosin Hcl ErAlfuzosin Hcl44$1,319
NitrofurantoinNitrofurantoin Macrocrystal31$838
Doxazosin Mesylate19$522
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst47$310
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip18$255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$212$81,69375 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 401 urology providers in New Jersey.

Other urology in Brick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →